Gradient
Denervation Technologies

Gradient Denervation Technologies Appoints Stanton Rowe to Board of Directors and Receives FDA Approval to Expand Early Feasibility Study

PARIS, FRANCE, October 22, 2024 — Gradient Denervation Technologies announced today that it has appointed medical device serial entrepreneur and executive Stanton Rowe to its board of directors, and that FDA has approved the expansion of the PreVail-PH2 Early Feasibility Read more

Gradient Denervation Technologies Enrolls First Patient in Early Feasibility Study of Pulmonary Artery Denervation System

PARIS, FRANCE, March 6, 2024 — FDA-Approved US study intended to evaluate pulmonary artery denervation in heart failure patients with WHO Group 2 Pulmonary Hypertension Read more

Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys

PARIS, FRANCE, SEPTEMBER 7, 2023

Thuja Capital and founding investor Sofinnova Partners also joined the round

The funds will enable the company to advance the clinical development of its unique, minimally invasive ultrasound-based catheter for the treatment of pulmonary hypertension, with initial focus on the Group 2 population, or heart failure accompanied by high pulmonary vascular resistance Read more

Gradient Denervation Technologies enrolls initial patient in first-in-human study of pulmonary artery denervation technology

PARIS, FRANCE, JUNE 1, 2023 — Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive device for treating certain heart failure patients with associated pulmonary hypertension, announced today the successful first patient enrollment in its first-in-human clinical study. Read more

Gradient Denervation Technologies announces appointment of Martin Grasse as Chief Executive Officer

PARIS, FRANCE, APRIL 7, 2022 - Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of heart failure patients with pulmonary hypertension, announced today the appointment of Martin Grasse as Chief Executive Officer. With over 15 years in the medical device industry, Grasse joins the company as it works to freeze the design of its novel catheter-based system and prepare for early clinical trials. Read more

Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

PARIS, FRANCE, SEPTEMBER 17, 2020 - Gradient Denervation Technologies announced the close of a €3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology. Read more